Search results for "Citalopram"

showing 9 items of 29 documents

2020

Withdrawal symptoms after discontinuation of antidepressants are common and have long been known. Typical symptoms after dose reduction or discontinuation of antidepressants are dizziness, drowsiness, headache, flu-like symptoms, hyperarousal, imbalance, insomnia, irritability, and nausea. Rebound, relapse, or recurrence associated with the underlying mental disorder may also occur. The occurrence of obsessive-compulsive symptoms (OCS) following abrupt discontinuation of antidepressants have not yet been reported. Here we report the development of OCS (obsessional suicidal thoughts) in a patient with major depressive disorder and absence of a previous obsessive-compulsive disorder following…

Pediatricsmedicine.medical_specialtyNauseabusiness.industryVenlafaxinemedicine.diseaseIrritabilityObsessive compulsive symptoms030227 psychiatryDiscontinuation03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinemedicineEscitalopramMajor depressive disordermedicine.symptombusiness030217 neurology & neurosurgeryDepression (differential diagnoses)medicine.drugFrontiers in Psychiatry
researchProduct

Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin

2001

Melatonin, the predominant product of the pineal gland, is involved in the maintenance of diurnal rhythms. Nocturnal blood concentrations of melatonin have been shown to be enhanced by fluvoxamine, but not by other serotonin reuptake inhibitors. Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes. Melatonin was found to be almost exclusively metabolized by CYP1A2 to 6-hydroxymelatonin and N-acetylserotonin with a minimal contribution of CYP2C19. Both reactions were potently in…

Serotoninendocrine systemmedicine.medical_specialty10050 Institute of Pharmacology and Toxicology610 Medicine & healthFluvoxamineCitalopramPharmacologyImipramineMelatonin2738 Psychiatry and Mental HealthPineal glandTheophyllineCytochrome P-450 CYP1A2Internal medicineDesipraminemedicineHumans2736 Pharmacology (medical)Pharmacology (medical)Enzyme InhibitorsMelatoninFluoxetineChemistryPsychiatry and Mental healthmedicine.anatomical_structureEndocrinologyFluvoxamineMicrosomes LiverAntidepressive Agents Second-Generation570 Life sciences; biologyReuptake inhibitorhormones hormone substitutes and hormone antagonistsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Vertical distribution of pharmaceuticals in lake sediments-citalopram as potential chemomarker

2012

The use of pharmaceuticals has increased enormously over the last few decades and serious concerns about their environmental fate and effects have arisen. Thus far, there is little knowledge about the historical pollution of the environment by pharmaceuticals. In the present study, sediment columns from three lake sites adjacent to wastewater treatment plants were collected, further divided in 2- or 2.5-cm slices, and analyzed for 15 pharmaceuticals by liquid chromatography-tandem mass spectrometry. In addition, sediment columns were historically interpreted by analyzing fecal sterols (coprostanol and cholesterol) as well as organic material and organic carbon. Several pharmaceuticals were …

Total organic carbonPollutionGeologic SedimentsHealth Toxicology and Mutagenesismedia_common.quotation_subjectSedimentCitalopramContaminationCholestanolCoprostanolLakesSterolschemistry.chemical_compoundPharmaceutical PreparationschemistryWastewaterEnvironmental chemistryEnvironmental ChemistryEnvironmental scienceSewage treatmentEffluentWater Pollutants ChemicalEnvironmental Monitoringmedia_commonEnvironmental Toxicology and Chemistry
researchProduct

P-515 - CGI Rating to predict antidepressant treatment under naturalistic conditions

2012

Introduction Recent studies have shown that psychopathological rating by the Hamilton Depression Rating scale (HAMD) is well established and highly predictive for later response. In this study we aimed to find out if Clinical Global Impression (CGI) scale is suitable to guide antidepressive treatment under naturalistic conditions. Methods Inpatients with a major depressive disorder and treatment with citalopram were included and rated using in parallel the HAMD scale and the CGI scale weekly at baseline to day 35. According to CGI the sample has been divided in “CGI improver” (CGI = 2–4) and “CGI non-improver” (CGI = 5–6). Response was defined as HAMD sum score reduction by at least 50%. Re…

medicine.medical_specialtyCitaloprammedicine.diseasehumanitiesPsychiatry and Mental healthRating scalehealth services administrationInternal medicinemental disordersHamdClinical Global ImpressionmedicineMajor depressive disorderAntidepressantPsychiatryPsychologyPsychopathologymedicine.drugEuropean Psychiatry
researchProduct

Influence of gender on cytokine induced depression and treatment

2021

Abstract Background Cytokine treatment with Interferon-alpha (IFN-α) represents a clinical model of immune associated depression, but it remains unclear if it is of the same entity as major depressive disorder (MDD). The study focuses on possible gender differences in IFN-α induced depression and effects of a pre-emptive antidepressant treatment. Methods Data from 181 patients with chronic hepatitis C infection (cHC) without history of mental illnesses undergoing treatment with IFN-α 2a and ribavirin were re-analyzed for gender effects. Patients with a pre-emptive antidepressant therapy with Escitalopram (n = 90, verum group) to prevent IFN-induced depression were compared to patients who r…

medicine.medical_specialtyHamilton Anxiety Rating Scalebusiness.industryAlpha interferonmedicine.diseasePlacebo030227 psychiatry03 medical and health sciencesPsychiatry and Mental healthClinical Psychology0302 clinical medicineRating scaleInternal medicinemedicineMajor depressive disorderAntidepressantEscitaloprambusiness030217 neurology & neurosurgeryDepression (differential diagnoses)medicine.drugJournal of Affective Disorders
researchProduct

Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric di…

2012

BACKGROUND: Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. OBJECTIVE: To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-alpha in HCV-infected patients without a history of psychiatric disorders. DESIGN: Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) SETTING: 10 university and 11 academic…

medicine.medical_specialtyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineEscitalopram030212 general & internal medicinePsychiatryDepression (differential diagnoses)business.industryIncidence (epidemiology)Absolute risk reductionGeneral MedicineHepatitis Cmedicine.disease3. Good healthTolerability030211 gastroenterology & hepatologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: Reversal of chronic psychosocial stress-induce…

2010

The transcription factor CREB regulates adaptive responses like memory consolidation, addiction, and synaptic refinement. Recently, chronic psychosocial stress as animal model of depression has been shown to stimulate CREB transcriptional activity in the brain; this stimulation was prevented by treatment with the antidepressant imipramine, which inhibits both noradrenaline and serotonin reuptake. However, it was unknown whether the selective inhibition of serotonin reuptake is sufficient for inhibition of stress-induced CREB activation, as it is for the clinical antidepressant effect. Therefore, the effect of two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, wa…

medicine.medical_specialtyTranscription GeneticMice TransgenicCitalopramBiologyCitalopramCREBImipramineDrug Administration ScheduleMice03 medical and health sciences0302 clinical medicineGenes ReporterCREB in cognitionFluoxetineInternal medicinemedicineAnimalsPhosphorylationCyclic AMP Response Element-Binding ProteinTranscription factor030304 developmental biologyPharmacology0303 health sciencesFluoxetineBrain3. Good healthEndocrinologyGene Expression RegulationMechanism of actionbiology.proteinAntidepressantmedicine.symptomSelective Serotonin Reuptake InhibitorsStress Psychological030217 neurology & neurosurgerymedicine.drugEuropean Journal of Pharmacology
researchProduct

Efficacy and tolerance of a medication switch from Escitalopram to Venlafaxine in patients with Major Depressive Disorders

2017

medicine.medical_specialtybusiness.industrymedicineEscitalopramVenlafaxineIn patientPsychiatrybusinessmedicine.drugPharmacopsychiatry
researchProduct

Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care

2018

Introduction: Factors relating to the interpersonal relationship between the patient and their physician and social environment are important components, which contribute to their response to treatment for major depressive disorder. This study aimed to assess the influence of optimism, perfectionism, therapeutic alliance, empathy, social support, and adherence to medication regimen in the response to antidepressant treatments in the context of normal primary care clinical practice.Method: We conducted a prospective study in which 24 primary care physicians administered sertraline or escitalopram to 89 patients diagnosed with major depressive disorder. The response to treatment and remission…

medicine.medical_specialtylcsh:RC435-571psiquiatriaContext (language use)malalties mentals03 medical and health sciencesSocial supportprimary care0302 clinical medicinelcsh:PsychiatryInternal medicineMedicineEscitalopram030212 general & internal medicineProspective cohort studyempathyOriginal ResearchPsychiatrySertralinebusiness.industrytherapeutic alliancePrimary care physicianSocial environmentsocial supportmedicine.diseaseoptimismPsychiatry and Mental healthantidepressantsMajor depressive disorderperfectionismbusiness030217 neurology & neurosurgerymedicine.drugFrontiers in Psychiatry
researchProduct